EyePoint Pharmaceuticals Q1 net loss widens on increased R&D spending

EyePoint

06/05/2026 12:17

Overview

US biopharma firm's Q1 revenue dropped sharply due to prior year licensing revenue recognition

Q1 net loss widened as R&D and manufacturing costs rose for DURAVYU Phase 3 trials

Company ended Q1 with $223 mln in cash and investments, runway into Q4 2027

Outlook

EyePoint expects topline data from Phase 3 wet AMD trials beginning mid-2026

Company expects full enrollment in Phase 3 DME trials in Q3 2026, topline data in Q4 2027

EyePoint expects cash and investments to fund operations into Q4 2027

Result Drivers

INCREASED R&D SPENDING - Co said higher operating expenses were mainly due to ongoing DURAVYU Phase 3 trials for wet AMD and DME

MANUFACTURING SCALE-UP - Co cited increased costs from scaling up its commercial manufacturing facility

LOSS OF LICENSING REVENUE - Revenue decrease was mainly due to prior year recognition of deferred revenue from YUTIQ product rights license

Company press release: ID:nGNX5J5mmp

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Product Sales
$467,000
Q1 Net Income
-$84.83 mln
Q1 Basic EPS
-$0.99
Q1 Operating Expenses
$87.92 mln
Q1 Operating Income
-$87.23 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for EyePoint Inc is $34.00, about 147.3% above its May 5 closing price of $13.75

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)